Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC1 | P07992 | 1/20 | 0.52 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.50 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
| ▸ | CCR2 | P41597 | 1/20 | 0.45 |
| ▸ | VNN1 | O95497 | 2/20 | 0.45 |
| ▸ | GLS | O94925 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
| ▸ | IDH1 | O75874 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15961772 | 0.85 | ERCC1 (0.55) | ERCC1ERCC4LMNAMEP1AMEP1B | |
| SCHEMBL335418 | 0.84 | LMNA (0.56) | ERCC1ERCC4LMNAMEP1AMEP1B | |
| SCHEMBL3010497 | 0.83 | ERCC1 (0.50) | ERCC1ERCC4LMNAMEP1AMEP1B | |
| SCHEMBL2411845 | 0.83 | FFAR1 (0.55) | ERCC1ERCC4LMNAMEP1AMEP1B | |
| SCHEMBL6714339 | 0.82 | MAPK8 (0.56) | ERCC1ERCC4LMNAMEP1AMEP1B | |
| SCHEMBL4558717 | 0.82 | ERCC1 (0.52) | ERCC1ERCC4LMNAMEP1AMEP1B | |
| SCHEMBL200244 | 0.82 | ERCC1 (0.52) | ERCC1ERCC4LMNAMEP1AMEP1B | |
| SCHEMBL30860058 | 0.82 | ERCC1 (0.52) | ERCC1ERCC4LMNAMEP1AMEP1B | |
| SCHEMBL30489963 | 0.82 | MAPK8 (0.56) | ERCC1ERCC4LMNAMEP1AMEP1B | |
| SCHEMBL6714330 | 0.82 | ERCC1 (0.52) | ERCC1ERCC4LMNAMEP1AMEP1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435060-B2 | Acylamino bridged heterocyclic compound, and composition and application thereof | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2025-10-07 | — | — | US | disclosed |
| EP-3901147-B1 | ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-11-22 | — | — | EP | disclosed |
| US-20230026425-A1 | ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2023-01-26 | — | — | US | disclosed |
| EP-3901147-A1 | ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | Beijing Scitech-MQ Pharmaceuticals Limited (CN) | 2021-10-27 | — | — | EP | disclosed |
| US-8722681-B2 | N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases | NV REMYND (BE) | 2014-05-13 | — | — | US | disclosed |
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | NV REMYND (BE) | 2010-08-05 | — | — | US | disclosed |
| US-20090275583-A1 | ANTIVIRAL COMPOUNDS AND USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090275583-A1 | ANTIVIRAL COMPOUNDS AND USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2009-11-05 | — | — | US | disclosed |
| WO-2008127364-A2 | ANTIVIRAL COMPOUNDS AND USE THEREOF | MYRIAD GENETICS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008127364-A2 | ANTIVIRAL COMPOUNDS AND USE THEREOF | MYRIAD GENETICS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008123821-A1 | 4, 5-DIHYDRO-LH-IMIDAZOL-2-AMINE DERIVATIVES FOR USE IN THE TREATMENT OF RESPIRATORY, CARDIOVASCULAR, NEUROLOGICAL OR GASTROINTESTINAL DISORDERS | ALBIREO AB (SE) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026425-A1 | ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | RIPK1, RIPK3, RIPK4 | ERCC1 3987/4885ERCC4 4437/4885LMNA 2659/4885 |
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | SMN1; SMN2, HTT, SNCA | ERCC1 3366/4885ERCC4 4370/4885LMNA 80/4885 |
| US-20090275583-A1 | ANTIVIRAL COMPOUNDS AND USE THEREOF | MAVS, ZC3HAV1, EIF2AK2 | ERCC1 1820/4885ERCC4 377/4885LMNA 2620/4885 |
| US-12435060-B2 | Acylamino bridged heterocyclic compound, and composition and application thereof | RIPK1, RIPK3, RIPK4 | ERCC1 3987/4885ERCC4 4437/4885LMNA 2659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.